About tRNA wybutosine-synthesizing protein 2 homolog
tRNA wybutosine-synthesizing protein 2 homolog (TYW2) is a protein
from Homo sapiens identified by UniProt accession
Q53H54, 448 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | tRNA wybutosine-synthesizing protein 2 homolog |
| UniProt accession | Q53H54 |
| Gene | TYW2 |
| Organism | Homo sapiens |
| Length | 448 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (16)
Diseases linked to this target (Open Targets).
- mean platelet volume · score 0.34
- head and neck squamous cell carcinoma · score 0.07
- neoplasm · score 0.03
- cancer · score 0.02
- colorectal neoplasm · score 0.02
- colorectal carcinoma · score 0.01
- breast cancer · score 0.01
- lymph node metastatic carcinoma · score 0.01
- human papilloma virus infection · score 0.01
- COVID-19 · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q53H54-F1 | alphafold | PREDICTED | 85.06 | — |
Amino-acid sequence (448 residues)
MRENVVVSNM ERESGKPVAV VAVVTEPWFT QRYREYLQRQ KLFDTQHRVE KMPDGSVALP VLGETLPEQH LQELRNRVAP GSPCMLTQLP DPVPSKRAQG CSPAQKLCLE VSRWVEGRGV KWSAELEADL PRSWQRHGNL LLLSEDCFQA KQWKNLGPEL WETVALALGV QRLAKRGRVS PDGTRTPAVT LLLGDHGWVE HVDNGIRYKF DVTQCMFSFG NITEKLRVAS LSCAGEVLVD LYAGIGYFTL PFLVHAGAAF VHACEWNPHA VVALRNNLEI NGVADRCQIH FGDNRKLKLS NIADRVILGL IPSSEEGWPI ACQVLRQDAG GILHIHQNVE SFPGKNLQAL GVSKVEKEHW LYPQQITTNQ WKNGATRDSR GKMLSPATKP EWQRWAESAE TRIATLLQQV HGKPWKTQIL HIQPVKSYAP HVDHIVLDLE CCPCPSVG
Explore tRNA wybutosine-synthesizing protein 2 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets